Bayer Health Care Pharmaceuticals Inc. won’t be facing consolidated federal litigation over its Mirena intrauterine device, a long-term method of birth control.

Consolidating litigation in which plaintiffs allege the Mirena IUDs caused abnormal elevation of cerebrospinal fluid in their skulls could have some benefit, but there are not enough cases to justify centralizing cases for pretrial purposes, wrote John G. Heyburn II, chairman of the U.S. Judicial Panel on Multidistrict Litigation.